Maria Russell, MD, surgical oncologist at Winship Cancer Institute of Emory University presents Ocular Melanoma and Liver Metastases at the 2016 CURE OM Patient & Caregiver Symposium.
Hans E Grossinklaus, MD, Director, Section of Ocular Oncology & Pathology at Winship Cancer of Emory University presents the Specialized Program of Research Excellence (SPORE) Update: Uniting to Advance Ocular Melanoma Research at the 2016 CURE OM Patient & Caregiver Symposium.
Chris Bergstrom, MD in ocular oncology at Emory Eye Center in Atlanta, GA discusses the basics of ocular melanoma at the 2016 CURE OM Patient & Caregiver Symposium.
Maria Russell, MD, surgical oncologist at Winship Cancer Institute of Emory University presents Ocular Melanoma and Liver Metastases at the 2016 CURE OM Patient & Caregiver Symposium.
Hans E Grossinklaus, MD, Director, Section of Ocular Oncology & Pathology at Winship Cancer of Emory University presents the Specialized Program of Research Excellence (SPORE) Update: Uniting to Advance Ocular Melanoma Research at the 2016 CURE OM Patient & Caregiver Symposium.
Chris Bergstrom, MD in ocular oncology at Emory Eye Center in Atlanta, GA discusses the basics of ocular melanoma at the 2016 CURE OM Patient & Caregiver Symposium.
Basic information for discussion with a healthcare professional is provided here together with some background:
• An enlargement or the presence of tumors in the gland below a man’s bladder that produces fluid for semen ie, the prostate, may suggest benign prostatic hyperplasia (BPH) or prostate cancer
o Almost 8% of new cancer cases worldwide are attributed to this highly curable disease (proportion of patients surviving after 5 years = 98.9%)
o In the USA alone, prostate cancer is the most common non-skin cancer, diagnosed more often in African-American (1 in 5 cases) than white men (1 in 6 cases)
o Prostate cancer is strongly correlated with age, starting at about 50 years old and rising over the ensuing decades
o While debates over under- or over-treatment of prostate cancer continue, it is clear that management of the disease costs the USA an aggregate annual loss in productivity of $3.0 billion
o Moreover, prostate cancer is the third-leading cause of cancer-related deaths in the USA, mainly due to advanced or metastatic disease
Locally advanced Ca prostate
Courtesy : NCCN , Perez, Gunderson and Tepper
Brief outline on management
ADT, Radiotherapy, Surgery indications and Standard of care
What would you recommend as first line therapy for a 68 y/o woman with local pancreatic cancer and no metastatic disease with ECOG-1?
Chemoradiation: Rachna Shroff, MD
Surgical Resection: Yongyut Sirivatanauksorn, MD
Marlana Orloff, MD, from Thomas Jefferson University Hospital presents Understanding a Cluster of Uveal Melanoma Cases: Update from Huntersville, NC at the 2016 CURE OM Patient & Caregiver Symposium.
Darren Kies, MD, interventional radiologist at Winship Cancer Institute of Emory University presents Local Therapies for Uveal Melanoma Liver Metastases at the 2016 CURE OM Patient & Caregiver Symposium.
Basic information for discussion with a healthcare professional is provided here together with some background:
• An enlargement or the presence of tumors in the gland below a man’s bladder that produces fluid for semen ie, the prostate, may suggest benign prostatic hyperplasia (BPH) or prostate cancer
o Almost 8% of new cancer cases worldwide are attributed to this highly curable disease (proportion of patients surviving after 5 years = 98.9%)
o In the USA alone, prostate cancer is the most common non-skin cancer, diagnosed more often in African-American (1 in 5 cases) than white men (1 in 6 cases)
o Prostate cancer is strongly correlated with age, starting at about 50 years old and rising over the ensuing decades
o While debates over under- or over-treatment of prostate cancer continue, it is clear that management of the disease costs the USA an aggregate annual loss in productivity of $3.0 billion
o Moreover, prostate cancer is the third-leading cause of cancer-related deaths in the USA, mainly due to advanced or metastatic disease
Locally advanced Ca prostate
Courtesy : NCCN , Perez, Gunderson and Tepper
Brief outline on management
ADT, Radiotherapy, Surgery indications and Standard of care
What would you recommend as first line therapy for a 68 y/o woman with local pancreatic cancer and no metastatic disease with ECOG-1?
Chemoradiation: Rachna Shroff, MD
Surgical Resection: Yongyut Sirivatanauksorn, MD
Marlana Orloff, MD, from Thomas Jefferson University Hospital presents Understanding a Cluster of Uveal Melanoma Cases: Update from Huntersville, NC at the 2016 CURE OM Patient & Caregiver Symposium.
Darren Kies, MD, interventional radiologist at Winship Cancer Institute of Emory University presents Local Therapies for Uveal Melanoma Liver Metastases at the 2016 CURE OM Patient & Caregiver Symposium.
Mohammaed Khan, MD, PhD, DABR, radiation oncologist at Winship Cancer Institute of Emory University presents Localized Treatment for Metastatic Disease at the 2016 CURE OM Patient & Caregiver Symposium.
Richard Carvajal, MD presents Targeted Therapy for Uveal Melanoma and the Uveal Melanoma Clinical Research Landscape at the 2017 CURE OM Patient & Caregiver Symposium.
David Lawson, MD, from Winship Cancer Institute of Emory University presents Prognosis and Medical Oncology Follow-up of Uveal Melanoma at the 2016 CURE OM Patient & Caregiver Symposium
Plasma cell disorders is a difficult topic where most residents and students confuse with regarding to differentiating between various types of para-proteinemias or plasma cell dyscrasias. This simple presentation will highlight the key points in differentiating, diagnosing these orders. Initial management principles are discussed as well.
NIH Presentation Nov 2016 Neuroendocrine Tumor Clinical TrialsCACSNETS
NIH/NCI presentation provides an overview of and NIH clinical trials. Briefing covers: 1) Overview of GI and pancreatic Neuroendocrine Tumors (NETs) /Carcinoid Cancer;
2) Treatment options for patients with advanced GI and pancreatic NETs; 3) Clinical trials for/in patients with NETs
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
NVBDCP.pptx Nation vector borne disease control programSapna Thakur
NVBDCP was launched in 2003-2004 . Vector-Borne Disease: Disease that results from an infection transmitted to humans and other animals by blood-feeding arthropods, such as mosquitoes, ticks, and fleas. Examples of vector-borne diseases include Dengue fever, West Nile Virus, Lyme disease, and malaria.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
5. Uveal melanoma: pathophysiology
Location
Iris
% 5-year mts.
%10-year mts
4%
7%
Ciliary body
19%
33%
Choroides
15%
25%
Conjuntival melanoma is related more with its
cutaneous counterpart
Predrag Jovanovic et al.
Int J Clin Exp Pathol 2013;6(7):12301244
8. Uveal melanoma prognosis
Monosomy of chromosome 3 is the
most frequent chromosome aberration
in uveal melanoma (50%)
Class 1: low grade tumors with low metastatic risk
Class 2: high grade tumors with metastatic risk
chracterized by down-regulation of genes on
chromosome 3 and up-regulation of genes on
chromosome 8q.
9. BAP1: BCRA-1 associated protein-1 and metastatic
development of uveal melanoma
The gene encoding BAP-1 is located on chromosome
3p21.1 and is mutated in 80% of metastatic uveal
melanoma. BAP-1 is a enzyme that forms part of a
tumor-suppressor complex. BAP-1 mutation is associated
to metastatic behaviour
11. Ipilimumab in metastatic uveal melanoma
Outcome after compassionate use (USA, Italy):
1-year overall survival over 30%.
More common dose: 3 mg/Kg
Median overall survival 6 months (Italian use)
Toxicity experience and response similar to cutaneous
12. Uveal melanoma: rational for treatment
GNAQ and GNA11 are mutated in a mutually exclusive pattern (83% uveal):
these mutations are implicated in the stimulus of MAPK pathway via MEK.
GNAQ/GNA11 signals also via PLC(phospholipase C) and PKC (protein
kinase C), enzymes implicated in proliferation, invasion,apoptosis via ERK
Cancer Letters 2006;235:1-10
13. Therapeutic targets
• MEK inhibitors: (no response in wild-type GNAQ/GNA11)
– Selumetinib compared with temozolamide; 9 weeks benefit for
selumetinib for PFS
– MEK162
• PAK inhibitors: sotrastaurin (AEB071)/ enzastaurin.
– G1 cell cycle arrest
– Inhibition of PKC in GNAQ-mutant resulted in the inhibition of the
MAPK pathway.
A combination of a MEK and proteinkinase inhibitor could be a
perfect therapeutic combination
14. Conclusions
• 1. Metastases from melanoma can spread to almost
•
•
•
•
every anatomical location.
2. Uveal melanoma is the most common primary
malignancy of the eye
3. GNAQ and GNA11 are mutated in 80% of uveal
melanoma in a mutually exclusive pattern
4. Ipilimumab achieves a 30% survival in the first year in
uveal melanoma
5. MEK inhibitors and PAK inhibitors are key for
developing targeted therapies.